12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Relovair fluticasone furoate/vilanterol: Phase III data

Top-line data from a 12-week Phase III trial in about 500 patients with COPD showed that once-daily 100/25 µg Relovair fluticasone furoate/vilanterol missed the primary endpoint of superiority to twice-daily 250/50 µg Advair fluticasone propionate/salmeterol in 24-hour weighted mean FEV1 (p=0.267). Earlier this year, the partners reported that Relovair...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >